General Information of Drug (ID: DM57SVW)

Drug Name
benzamil Drug Info
Synonyms
Benzamil; 2898-76-2; UNII-04659UUJ94; N-(N-Benzylamidino)-3,5-diamino-6-chloropyrazine carboxamide; GNF-Pf-192; CHEMBL212579; CHEBI:34558; 04659UUJ94; 3,5-Diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)pyrazinecarboxamide; 3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide; Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)-; Spectrum3_001823; Prestwick1_000657; Prestwick3_000657; Prestwick2_000657; Prestwick0_000657; Lopac-B-2417; AC1L33CQ; Lopac0_000211; KBioGR_000300
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
108107
ChEBI ID
CHEMBL212579
CAS Number
CAS 2898-76-2
TTD Drug ID
DM57SVW
VARIDT Drug ID
DR01348

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
citric acid DM80YI7 Discovery agent N.A. Investigative [8]
flufenamate DMN8AP0 Discovery agent N.A. Investigative [4]
malic acid DMU3O5H Discovery agent N.A. Investigative [8]
phenamil DMJLUFM Discovery agent N.A. Investigative [4]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Triamterene DM2HU9I Congestive heart failure BD10 Approved [9]
VX-371 DMSTHG1 Cystic fibrosis CA25 Phase 2 [10]
S3969 DM84DMW Discovery agent N.A. Investigative [11]
Drug Name Drug ID Indication ICD 11 Highest Status REF
agmatine DMSBZ29 Discovery agent N.A. Investigative [12]
A-317567 DMGWO9J Discovery agent N.A. Investigative [12]
THA-902 DMKCY0X Fibromyalgia MG30.01 Investigative [12]
arcaine DMXOYK0 Discovery agent N.A. Investigative [12]
GMQ DMM0ZKQ Discovery agent N.A. Investigative [12]
APETX2 DM0JW2V Pain MG30-MG3Z Investigative [13]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [14]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [15]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [16]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [17]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [18]
Verapamil DMA7PEW Angina pectoris BA40 Approved [19]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [20]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [21]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [22]
Propranolol DM79NTF Angina pectoris BA40 Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Secretin (SCT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [24]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [25]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [26]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [27]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [28]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [29]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [30]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [31]
Pentagastrin DMRCLZB Diagnostic imaging N.A. Approved [32]
CHLORIDE DM1TJXA Solid tumour/cancer 2A00-2F9Z Phase 3 [33]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [34]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [35]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [7]
Arsenic DMTL2Y1 N. A. N. A. Approved [36]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [29]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [7]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [37]
PMID28870136-Compound-52 DMFDERP N. A. N. A. Patented [38]
Milchsaure DM462BT Pruritus EC90 Investigative [39]
3-iodothyronamine DM3L0F8 Discovery agent N.A. Investigative [40]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acid-sensing ion channel 3 (ASIC3) TTLGDIS ASIC3_HUMAN Blocker (channel blocker) [2]
Amiloride-sensitive sodium channel (ENaC) TTQM7TE SCNNA_HUMAN; SCNNB_HUMAN; SCNNG_HUMAN; SCNND_HUMAN Blocker (channel blocker) [3]
Polycystic kidney disease 2-like 1 (TRPP2) TTAHD89 PK2L1_HUMAN Blocker (channel blocker) [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Secretin (SCT) OTV3MLOO SECR_HUMAN Gene/Protein Processing [6]
Sodium/hydrogen exchanger 7 (SLC9A7) OTVDLTYA SL9A7_HUMAN Gene/Protein Processing [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4145).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 684).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 742).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505).
5 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
6 Activation of transepithelial ion transport by secretin in human intestinal Caco-2 cells. Jpn J Physiol. 2000 Apr;50(2):215-25. doi: 10.2170/jjphysiol.50.215.
7 Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network. J Biol Chem. 2001 May 18;276(20):17387-94. doi: 10.1074/jbc.M101319200. Epub 2001 Feb 26.
8 Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12569-74.
9 Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18.
10 The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652.
11 Small molecule activator of the human epithelial sodium channel. J Biol Chem. 2008 May 2;283(18):11981-94.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
13 Challenges in analgesic drug development. Clin Pharmacol Ther. 2009 Oct;86(4):447-50.
14 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
15 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
16 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
17 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
18 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
19 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
20 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
21 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
22 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
23 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
24 Retinoic acid-induced human secretin gene expression in neuronal cells is mediated by cyclin-dependent kinase 1. Ann N Y Acad Sci. 2006 Jul;1070:393-8. doi: 10.1196/annals.1317.051.
25 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
26 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
27 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
28 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
29 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
30 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
31 Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006 Mar;28(2):99-103. doi: 10.1016/j.braindev.2005.05.005. Epub 2005 Sep 15.
32 Secretin inhibits canine gastric acid secretion in response to pentagastrin by modulating gastric histamine release. J Pharmacol Exp Ther. 1996 Nov;279(2):718-23.
33 The influence of secretin on ion transport in the human jejunum. Gut. 1973 Jun;14(6):485-90. doi: 10.1136/gut.14.6.485.
34 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
35 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
36 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
37 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
38 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
39 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
40 Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.